NCT06745583 2026-04-09
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Phase 2 Recruiting
Elixiron Immunotherapeutics (Hong Kong) Ltd.
The University of Hong Kong
University of Thessaly
NRG Oncology
University of Massachusetts, Amherst
Northwestern University
Korea University